Product Name: CBD (Cannabidiol) Isolate
Synonyms: hemp oil 50%CBD total cannabinoids 90%;(-)-2-[(3R,4R)-p-Mentha-1,8-dien-3β-yl]-5-pentylresorcinol;C07578;Methanol( test Cannabidiol 1.0 mg/mL);(-)-trans-2-p-mentha-1,8-dien-3-yl-5-pentylresorcinol;(-)-trans-Cannabidiol;1,3-Benzenediol,2-[(1R,6R)-3-Methyl-6-(1-Methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-;Cannabidiol (exempt preparation)
Chemical Properties Off-White Solid
Uses Major non-psychoactive constituent of Cannabis. Exhibits multiple bioactivities including anticonvulsant, anxiolytic and anti-inflammatory effects. The (+)-isomers were more active than the (-)-isomers.
Cannabidiol[CBD] is the main non-psychotropic component of the glandular hairs of Cannabis sativa. It displays a plethora of actions including anticonvulsive, sedative, hypnotic, antipsychotic, and anti-inflammatory and neuroprotective properties. It is a major phyto-cannabinoid, accounting for up to 40% of the Cannabis plant’s extract, that binds to a wide variety of physiological targets of the endocannabinoid system within the body. Although the exact medical implications are currently being investigated, CBD has shown promise as a therapeutic and pharmaceutical drug target. In particular, CBD has shown promise as an analgesic, anticonvulsant, muscle relaxant, anxiolytic, antipsychotic and has shown neuroprotective, anti-inflammatory, and antioxidant activity, among other currently investigated uses.
Cannabidiol was isolated from marijuana in the late 1930s, but only in the 1963 were its structure and stereochemistry first elucidated. Early studies focusing on CBD pharmacology started in the 1970s, with the first relevant finding concerning its hypnotic and anticonvulsant properties, published in 1981. Since then, a large body of pharmacological effects has been demonstrated, both in preclinical and in clinical studies.